<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465008</url>
  </required_header>
  <id_info>
    <org_study_id>PERPRO2014_V2</org_study_id>
    <nct_id>NCT02465008</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Levobupivacaine in Breast Augmentation</brief_title>
  <official_title>Analgesic Efficacy of Levobupivacaine Administration in Periprosthetic Breast Augmentation With Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valencia University General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valencia University General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levobupivacaine is effective in the acute
      postoperative pain treatment in periprosthetic breast augmentation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the most common plastic surgery is breast augmentation using prosthesis ( mammoplasty
      Surgery with cohesive silicone gel prosthesis insubpectoral plane). Remains challenging
      management of acute postoperative pain that allows for early discharge of patients. To this
      end the following objectives are proposed: evaluate the analgesic efficacy of L-Bupivacaine
      0.25% vs. Placebo (saline) administered irrigation into the surgical pocket bilaterally
      intraoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Not recruiting
  </why_stopped>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported postoperative pain. evaluated by a Visual Analog Scale (VAS) at rest and movement (cough).</measure>
    <time_frame>at 6 hours the early postoperative period (after the end of anesthesia)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>levobupivaciane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator (saline solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group (saline solution) 60 ml (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <arm_group_label>levobupivaciane group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Comparator (saline solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women&gt; 18 and &lt;= 65 years

          -  Mammoplasty Surgery with cohesive silicone gel prosthesis in subpectoral plane

          -  ASA I and II

          -  Informed consent signed

        Exclusion Criteria:

          -  Rejection of the patient

          -  ASA III or higher

          -  Other conditions that warrant their inclusion as medically indicated (eg psychiatric
             illness).

          -  Allergy to NSAIDs, local anesthetics and / or morphine

          -  Patients treated for chronic pain

          -  Placement of drains for surgical needs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Valencia University General Hospital</investigator_affiliation>
    <investigator_full_name>Severiano Marin Bertoli</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>postoperative</keyword>
  <keyword>Patient-reported</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

